Laura Ruglioni

Laura Ruglioni

Auto-generated profile, based on publicly available information

Laura Ruglioni

IRCCS Fondazione Stella Maris, Scientific Institute of Child Neurology and Psychiatry, Calambrone, Pisa, Italy

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2013 in Comprehensive Psychiatry
Verified
Journal Article
Closed access
GMGabriele Masi
Gabriele Masi
Pietro MuratoriPietro Muratori
Pietro Muratori
AMAzzurra Manfredi
Azzurra Manfredi
FLFrancesca Lenzi
Francesca Lenzi
LPLisa Polidori
Lisa Polidori
AMAnnarita Milone
Annarita Milone

26 May 2015 in Administration and Policy in Mental Health and Mental Health Services Research
Verified
Journal Article
Closed access
PDF file
Pietro MuratoriPietro Muratori
Pietro Muratori
AMAnnarita Milone
Annarita Milone
AMAzzurra Manfredi
Azzurra Manfredi
LPLisa Polidori
Lisa Polidori
LRLaura Ruglioni
Laura Ruglioni
JLJohn E. Lochman
John E. Lochman

18 March 2022 in Children
Verified
Journal Article
Open access
PDF file
SBStefano Berloffa
Stefano Berloffa
ASAndrea Salvati
Andrea Salvati
MDMaria Giulia D'Acunto
Maria Giulia D'Acunto
PFPamela Fantozzi
Pamela Fantozzi
EIEmmanuela Inguaggiato
Emmanuela Inguaggiato
GMGabriele Masi
Gabriele Masi
Although Attention Deficit Hyperactivity Disorder (ADHD) has been related to an increased risk for behavioral addictions, the relationship between ADHD and Internet Gaming Disorder (IGD) is still debated. The aim of this study is to address this topic by exploring the prevalence of IGD in a consecutive sample of ADHD youth, compared to a normal control group, and by assessing selected psychopathological and cognitive features in ADHD patients with and without IGD. One hundred and eight patients with ADHD (mean age 11.7 ± 2.6 years, 96 males) and 147 normal controls (NC) (mean age 13.9 ± 3.0 years, 114 males) were included in the study and received structured measures for IGD. In the ADHD group, 44% of the sample were above the IGD cut-off, compared to 9.5% in the NC group. ADHD patients with IGD presented with greater severity and impairment, more severe ADHD symptomatology, more internalizing symptoms, particularly withdrawal/depression and socialization problems, and more prominence of addiction and evasion dimensions. A binary logistic regression showed that the degree of inattention presented a greater weight in determining IGD. These findings may be helpful for identifying, among ADHD patients, those at higher risk for developing a superimposed IGD.

19 June 2014 in Prevention Science
Verified
Journal Article
Closed access
PDF file
Pietro MuratoriPietro Muratori
Pietro Muratori
IBIacopo Bertacchi
Iacopo Bertacchi
CGConsuelo Giuli
Consuelo Giuli
LLLavinia Lombardi
Lavinia Lombardi
SBSilvia Bonetti
Silvia Bonetti
JLJohn E. Lochman
John E. Lochman

13 September 2016 in Criminal Behaviour and Mental Health
Verified
Journal Article
Closed access
PDF file
Pietro MuratoriPietro Muratori
Pietro Muratori
MPMarinella Paciello
Marinella Paciello
CBCarlo Buonanno
Carlo Buonanno
AMAnnarita Milone
Annarita Milone
LRLaura Ruglioni
Laura Ruglioni
GMGabriele Masi
Gabriele Masi

1 March 2019 in Neuropsychiatric Disease and Treatment
Verified
Journal Article
Open access
PDF file
GMGabriele Masi
Gabriele Masi
PFPamela Fantozzi
Pamela Fantozzi
AVArianna Villafranca
Arianna Villafranca
ATAnnalisa Tacchi
Annalisa Tacchi
FRFederica Ricci
Federica Ricci
SCSamuele Cortese
Samuele Cortese
Purpose: Methylphenidate (MPH), the first-line medication in children with attention-deficit/hyperactivity disorder (ADHD), is associated with increased risk of sleep disorders. Melatonin has both hypnotic and chronobiotic properties that influence circadian rhythm sleep disorders. This study explores the effectiveness of melatonin in children with ADHD who developed sleep problems after starting MPH. Patients and methods: This study, based on a clinical database, included 74 children (69 males, mean age 11.6±2.2 years) naturalistically treated with MPH (mean dosage 33.5±13.5 mg/d). The severity of sleep disorder (sleep onset delay) was recorded at baseline and after a follow-up of at least 4 weeks using a seven-point Likert scale according to the Clinical Global Impression Severity score. Effectiveness of melatonin on sleep (mean dosage 1.85±0.84 mg/d) after 4 weeks was assessed using a seven-point Likert scale according to the Clinical Global Impression Improvement (CGI-I) score, and patients who scored 1 (very much improved) or 2 (much improved) were considered responders. Results: Clinical severity of sleep disorders was 3.41±0.70 at the baseline and 2.13±1.05 after the follow-up (P<0.001). According to the CGI-I score, 45 patients (60.8%) responded to the treatment with melatonin. Gender and age (children younger and older than 12 years) did not affect the response to melatonin on sleep. Patients with or without comorbidities did not differ according to sleep response. Specific comorbidities with disruptive behavior disorders (oppositional defiant disorder or conduct disorder), affective (mood and anxiety) disorders and learning disabilities did not affect the efficacy of melatonin on sleep. Treatment was well tolerated, and no side effects related to melatonin were reported. Conclusion: In children with ADHD with sleep problems after receiving MPH treatment, melatonin may be an effective and safe treatment, irrespective of gender, age and comorbidities.